Trial Profile
A Biomarker Analysis of Nivolumab in Previously Treated Advanced Gastric Cancer(WJOG10417GTR)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Feb 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Biomarker; Therapeutic Use
- 21 Jan 2023 Results of a biomarker analysis assessing LAG3-related factors to predict response to nivolumab monotherapy in advanced gastric cancer presented at the 2023 Gastrointestinal Cancers Symposium
- 13 Sep 2022 Results (between August 2018 and November 2020) assessing the prognostic impact of these subsets remains to be determined, particularly in advanced gastric cancer patients receiving nivolumab monotherapy that provides limited efficacy, presented at the 47th European Society for Medical Oncology Congress.
- 13 Sep 2022 Results (n=91) assessing profiling of myeloid cells associated with prognosis in nivolumab monotherapy for advanced gastric cancer, presented at the 47th European Society for Medical Oncology Congress.